![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Zhu, Zhengfei; Ni, Jianjiao; Cai, Xuwei; Su, Shengfa; Zhuang, Hongqing; Yang, Zhenzhou; Chen, Ming; Ma, Shenglin; Xie, Conghua; Xu, Yaping; Li, Jiancheng; Ge, Hong; Liu, Anwen; Zhao, Lujun; Rao, Chuangzhou; Xie, Congying; Bi, Nan; Hui, Zhouguang; Zhu, Guangying; Yuan, Zhiyong; Wang, Jun; Zhao, Lina; Zhou, Wei; Rim, Chai Hong; Navarro-Martin, Arturo; Vanneste, Ben G. L.; De Ruysscher, Dirk; Choi, J. Isabelle; Jassem, Jacek; Chang, Joe Y.; Kepka, Lucyna; Kasmann, Lukas; Milano, Michael T.; Houtte, Paul van; Suwinski, Rafal; Traverso, Alberto; Doi, Hiroshi; Suh, Yang-Gun; Noel, Georges; Tomita, Natsuo; Kowalchuk, Roman O.; Sio, Terence T.; Li, Baosheng; Lu, Bing und Fu, Xiaolong
(2022):
International consensus on radiotherapy in metastatic non-small cell lung cancer.
In: Translational Lung Cancer Research, Bd. 11, Nr. 9
2017
Laethem, Jean-Luc Van; Riess, Hanno; Jassem, Jacek; Haas, Michael; Martens, Uwe M.; Weekes, Colin; Peeters, Marc; Ross, Paul; Bridgewater, John; Melichar, Bohuslav; Cascinu, Stefano; Saramak, Piotr; Michl, Patrick; Brummelen, David Van; Zaniboni, Alberto; Schmiegel, Wollf; Dueland, Svein; Giurescu, Marius; Garosi, Vittorio L.; Roth, Katrin; Schulz, Anke; Seidel, Henrik; Rajagopalan, Prabhu; Teufel, Michael und Childs, Barrett H.
(2017):
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
In: Targeted Oncology, Bd. 12, Nr. 1: S. 97-109
2016
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe und Piccart-Gebhart, Martine
(2016):
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 3: S. 357-366